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Abstract 
BACKGROUND: Extensive intracellular and extracellular formation of advanced glycation end-products (AGEs) is 
considered a causative factor for vascular injury triggered by hyperglycemia in diabetes. The hyperglycemia will 
cause accumulation of AGEs, damage to pericytes, nerve growth factor (NGF), glial acid fibrillary protein (GFAP) 
and increase in vascular endothelial growth factor (VEGF). 
AIM: This study aimed to assess the efficacy of RAGE inhibition in suppressing the development and progression 
of diabetic retinopathy through modulation of the inflammatory pathway involving NGF, GFAP, and VEGF. 
METHODS: The design was in vivo experimental study. Thirty white rats were induced with Alloxan monohydrate. 
Rats were divided into 5 groups, normal, negative control, groups with an anti-RAGE dose of 1 μg/uL, the dose of 
10 μg/uL and 100 μg/uL. After 4 weeks of treatment, HbA1c, NGF, and GFAP levels were measured using ELISA. 
Quantification of VEGF expression was done using the ImageJ® application. Data was expressed with mean ± 
SD. Independent T-test with ANOVA and Tukey's post hoc was done.  
RESULTS: RAGE inhibitors yielded a significant decrease in blood glucose and HbA1c levels. VEGF and RAGE 
expression were reduced in anti-RAGE groups in various doses. Inhibition of RAGE reduced the damage of 
retinal pericytes, by reducing GFAP and increasing NGF, and reduced the formation of new blood vessels, by 
decreasing VEGF expression, in diabetic retinopathy. 
CONCLUSION: Inhibition of receptor for advanced glycation end-products (RAGE) was effective in suppressing 
the development and progression of diabetic retinopathy. 
 
 
 
 
 
 
Introduction 
 
Diabetes is a life-threatening disease 
associated with deadly complications such as 
cardiovascular disease, stroke, and microvascular 
diseases. Worldwide population with diabetes is 
estimated to be 285 million adults in 2010 and 
predicted to reach 439 million adults in 2030 with a 
total overall prediction of a 54% increase [1], [2]. 
Extensive intracellular and extracellular formation of 
advanced glycation end-products (AGEs) is 
considered a causative factor for vascular injury 
triggered by hyperglycemia in diabetes. Mechanisms 
related to and without the role of receptors are known 
to play a role in cellular dysfunction and tissue 
damage caused by AGE. Receptors for AGE (RAGE) 
were initially found as AGE binding receptors and are 
now known as pro-inflammatory molecules that make 
up the danger signals of mediation to the body. RAGE 
is included in the pattern-recognition receptors 
associated with innate and adaptive immunity. 
Endogenous and exogenous ligands include AGE, 
high-mobility group 1 (HMGB1), calcium-binding S100 
protein group, β2-integrin Mac/CD11b, amyloid β-
peptide, b-sheet fibrils, advanced oxidation protein 
products (AOPPs), complement C3a, 
lipopolysaccharides (LPS), and phosphatidylserine on 
the surface of apoptotic cells [3]. Activation of RAGE 
by ligand will cause activation of nuclear factor-κB 
(NF-κB) and other signalling pathways through 
stimulation of ERK (extracellular signal-regulated 
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kinase) 1 / 2, p38 MAPK (mitogen-activated-protein-
kinase)-JNK (c-Jun N-terminal kinases), JAK (Janus-
kinase)-STAT (signal transducer and activator of 
transcription), and Rac-Cdc42, many of which are the 
results and causes of reactive oxygen species (ROS) 
[4], [5].  
Furthermore, expression of inflammatory 
cytokines increases, leading to an inflammatory 
response with cellular migration and proliferation. The 
hyperglycemia will cause accumulation of AGEs, 
which will cause the death of intramural pericyte and 
thinning of the basement membrane so that it will 
reduce the blood supply to the retina. AGEs will cause 
an increase in ROS, increase in damage to pericytes, 
nerve growth factor (NGF), glial acid fibrillary protein 
(GFAP) and increase in vascular endothelial growth 
factor (VEGF), so that blood vessels will form in the 
retina. The massive occurrence of this process will 
cause interference with the retina [6], [7]. 
This study was the pilot study to assess the 
efficacy of RAGE inhibition in suppressing the 
development and progression of diabetic retinopathy 
through modulation of the inflammatory pathway 
involving NGF, GFAP, and VEGF in vivo. 
 
 
Material and Methods 
 
The design of the study was in vivo 
experimental study, using Wistar strains (Rattus 
norvegicus) white rats. This study was approved by 
the Bioethical Committee, Faculty of Medicine, 
Sriwijaya University-General Hospital Mohammad 
Hoesin (no. 198/kptfkunsri-rsmh/2018). 
 
Subjects Preparation and Anti-RAGE 
 Treatment 
This study involved as many as 30 white rats 
(Rattus norvegicus) aged 2 months, bodyweight of 
180-200 grams, with an equal number of animal 
gender, were conditioned in the housing of plastic 
cages, at room temperature, humidity level at 40-70%, 
with a dark-light cycle of 12 hours. Rats were fed with 
standard feed and drinking water ad libitum. Rats 
were induced with alloxan monohydrate (Sigma-
Aldrich, St. Louis, Missouri, USA) 120 mg/kg BW, 
intraperitoneally.  
Blood sugar levels were examined by 
Glucose assay (DiaSys Diagnostic Systems GmbH, 
Waterbury, Connecticut, USA). If the blood sugar level 
was more than 200 mg/dL, then a 10% glucose drink 
was given to elevate the blood sugar level, once every 
1 week. Alloxan monohydrate injection was performed 
for 12 weeks. Rats were divided into 5 groups, 1: 
normal, 2: negative control, 3, 4 and 5, respectively: 
Anti-RAGE (Abcam, Cambridge, UK) dose of 1 
μg/uL, the dose of 10 μg/uL and 100 μg/uL, in a single 
dose. Rats were euthanised by ketamine anaesthetic 
dose of 100 mg/kg BW, intraperitoneally. Blood 
collection from retro-orbital plexus was performed to 
estimate blood sugar and HbA1c levels. The serum 
was homogenised by centrifugation at 3000 rpm for 
20 minutes. Collection of retinas was carried out, 
where some were put into 10% NBF and part of the 
tissue was processed for homogenisation by 
centrifugation at 10,000 rpm, 4⁰C, for 30 minutes. 
 
HbA1c, NGF and GFAP examination 
HbA1c, NGF (Cloud-Clone Corp®, Texas, 
USA), and GFAP levels (Cloud-Clone Corp®, Texas, 
USA) were measured using the ELISA (Enzyme-
Linked Immunosorbent Assay) method. A total of 10 
ml supernatant was inserted into the microplate well. 
Then incubation for 30 minutes at 37°C was carried 
out. Afterwards, 50 μL of conjugate HRP was added 
to the microplate well, then incubated for 30 minutes 
at 37°C. 50 μL of chromogen A and chromogen B was 
added to the microplate well, then incubated for 15 
minutes, at 37°C. 50 μL stop solution was added to 
the microplate well. Then the microplate was inserted 
into the ELISA reader (Bio-rad®, Hercules, California, 
USA) with a wavelength of 450 nm, so that the Optical 
Density (OD) value was obtained. OD values were 
converted to levels. 
 
VEGF and RAGE examination 
The ophthalmic slices were obtained from the 
euthanised rats and stored at 10% NBF. The 
ophthalmic slices were then fixed, treated with paraffin 
blocks and cut into 4 um thick. Sections were 
deparaffinized with concentrated xylene and ethanol 
with various concentrations (100%, 90%, 80% and 
70%).  
Antigen retrieval was done by microwave 
using the Heat-Induced Antigen Retrieval (HIAR) 
method using pH 6.0 Na-citrate for 15 minutes and 
blocked by blocking solution (3% serum goat in 0.3% 
Triton X in PBS). Slides were washed with PBS 3 
times and incubated with anti-VEGF (1:100), anti-
RAGE (1:100) overnight at 4°C. Then counterstain 
and mounting were performed. Quantification was 
done using the ImageJ® application. 
 
Statistical Analysis 
Statistical analysis was done with SPSS for 
Windows (SPSS Inc., Chicago, Illinois, USA). Data 
was expressed with mean ± SD. Independent T-test 
with ANOVA Tukey's post hoc was done. Significance 
was set if the p-value was less than 0.05. 
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Results 
 
As exhibited in Table 1, there was a decrease 
in body weight on diabetic rats compared to normal. 
RAGE inhibitors increased body weight as the dose 
increased. The mean blood glucose levels of diabetic 
rats were higher when compared to normal.  
Table 1: Body Weight, Blood Glucose and HbA1c Levels 
Parameters Normal Negative 
Control 
Dose 1 μg/uL Dose 10 
μg/uL 
Dose 100 
μg/uL 
Body weight (g) 313  12.0* 187  11.3 189  12.5 195  11.6* 223  15.7* 
Blood glucose 
(mg/dL) 
91.4  8.9* 382  21.5 345  23.3* 321  26.9* 307  27.9* 
HbA1c (%) 5.89  0.98* 15.89  7.81 13.29  9.18* 12.09  7.23* 11.89  6.12* 
Data were mean  SD; *p < 0.05 compared to negative control. 
 
Further, diabetics rats possessed higher 
levels of HbA1c compared to normal. Reversely 
RAGE inhibitors yielded a significant decrease in 
blood glucose and HbA1c levels compared to the 
negative control, as the dose increased (Table 1). 
Table 2: Level of Retinal NGF and GFAP 
Parameters Normal Negative 
Control 
Dose 1 μg/uL Dose 10 
μg/uL 
Dose 100 
μg/uL 
NGF (pg/mL) 113.4  9.7* 67.3  4.3 75.1  9.5* 85.3  7.6* 97.5  8.7* 
GFAP (ng/mL) 41.4  2.9* 182.2  9.5 165.3  13.3* 132.1  11.9* 109.2  8.9* 
Data were mean  SD; *p < 0.05 compared with the negative control. 
 
RAGE inhibitor decreased pericyte death 
shown by the decreased level of GFAP and increased 
NGF level (Table 2). As shown in Table 2, the mean 
NGF levels of people with diabetes were lower 
compared to normal. In contrary, diabetic rats 
possessed higher levels of GFAP compared to 
normal. RAGE inhibitors increased NGF levels and 
decreased GFAP levels in a dose-dependent manner. 
 
Figure 1: Immunohistochemistry of VEGF in Retina (400 x); A) 
Normal; B) Negative Control; C) Dose 1 μg/uL; D) Dose 10 μg/uL; 
E) Dose 100 μg/uL; F) VEGF expression (%) 
 
As exhibited in Figure 1 and Figure 2, VEGF 
and RAGE expressions were distinctly higher in 
people with diabetes compared to normal. VEGF and 
RAGE expressions were reduced in anti-RAGE 
groups in various doses. Increased doses resulted in 
a more diminished level of VEGF and RAGE. 
 
Figure 2: Immunohistochemistry of RAGE in Retina (400 x); A) 
Normal; B) Negative Control; C) Dose 1 μg/uL; D) Dose 10 μg/uL; 
E) Dose 100 μg/uL; F) RAGE expression (%) 
 
 
Discussion 
 
Chronic complications of diabetes mellitus are 
health problems that had become a global priority. 
AGEs are believed to play a vital role in the 
pathophysiology of various complications of diabetes 
mellitus. AGE accumulation in chronic diabetes 
mellitus causes pericyte death and thickening of the 
basement membrane, which causes incompetence of 
blood vessel walls. AGEs also stimulate RAGE 
expression which leads to activation of VEGF 
production which in turn triggers angiogenesis in the 
retina. Also, AGE induces pericytes apoptotic cell 
death through interaction with RAGE and VEGF 
induction. It is becoming clear that hypoxia plays an 
important role in all diabetes complications as it has 
been postulated that hyperglycemia induces a 
pseudohypoxia state. Cell adaptive response to 
hypoxia is mediated by the induced hypoxia-1 factor 
(HIF-1a) [8]. VEGF is a powerful mitogen for 
endothelial cells that triggers proliferation, migration 
and tube formation which causes the growth of new 
blood vessels. Also, AGE induces VEGF expression 
in cell culture and animal models, so it is considered 
to be involved in the pathogenesis of diabetic 
retinopathy. GFAP is an intermediate filament protein 
that is present in retinal glial cells (ganglion cells) and 
retinal astrocytes. Retinal glia (astrocytes, Muller cells, 
and microglia) is a sensitive indicator of retinal tissue 
Basic Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
3924                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
injury and is very affected in the condition of diabetes 
due to the formation of AGE [9], [10], [11], [12], [13], 
[14]. 
This study showed that inhibition of RAGEs 
was able to reduce pericytes damage by reducing the 
formation of ROS due to accumulation of AGEs. The 
levels of NGF and GFAP that were assessed in this 
study showed that inhibition of RAGEs was able to 
reduce pericytes damage. Decreased accumulation of 
AGEs reduced VEGF expression so that the formation 
of new blood vessels in the retina could be prevented 
[15]. These results suggest a new treatment strategy 
for diabetic retinopathy conditions. 
In conclusion, inhibition of RAGE reduced the 
damage of retinal pericytes, by reducing GFAP and 
increasing NGF, and reduced the formation of new 
blood vessels, by decreasing VEGF expression in 
diabetic retinopathy. Inhibition of receptor for 
advanced glycation end-products (RAGE) was 
effective in suppressing the development and 
progression of diabetic retinopathy. 
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